Breaking News Instant updates and real-time market news.

Atkore sees FY18 adj. EPS $1.45-$1.60, consensus $1.60

Sees FY18 adjusted EBITDA $245M-$260M.

29

Nov

ATKRAtkore

$20.01

0.4 (2.04%)

08/09/17

FBCO

08/09/17UPGRADETarget $22FBCOOutperform

Atkore upgraded to Outperform from Neutral at Credit Suisse

Credit Suisse analyst Julian Mitchell upgraded Atkore to Outperform from Neutral following its sharp share price drop upon the release of Q3 figures. The analyst thinks the concerns that he had highlighted in his initiation report in mid-2016 are now fully factored in. Mitchell also lowered his price target on the shares to $22 from $26 due to his lowered forecasts, reflecting a weaker non-res demand outlook and increased raw material headwinds.

08/09/17

WELS

08/09/17NO CHANGEWELS

Atkore weakness overdone, says Wells Fargo

Wells Fargo says that the 22% plunge in Atkore's stock was overdone. The firm thinks the decline prices in further downturns in the company's fiscal 2018 earnings outlook relative to its sector. It believes that the stock now "more than" prices in all upcoming risks, and it expects the shares to increase "modestly" in the nearer term. Wells keeps an Outperform rating on the shares.

10/11/17

UBSW

10/11/17DOWNGRADETarget $21UBSWNeutral

Atkore downgraded to Neutral from Buy at UBS

UBS analyst Christopher Belfiore downgraded Atkore to Neutral saying positive non-residential construction trends are largely priced in with the shares up 25% since mid-August. The analyst also remains cautious on the company's margin expansion opportunity given a more challenging pricing environment. He raised his price target for the stock to $21 from $19.

AT&T Mobility has reached a tentative agreement with the Communications Workers of America in Mobility Orange contract negotiations. The four-year agreement, which will be submitted to the union's membership for a ratification vote in coming days, covers about 20,000 employees in 36 states and the District of Columbia - AT&T's Mobility Orange unit, which encompasses CWA Districts 1, 2-13, 4, 7 and 9.

Pfizer announced that the United States FDA has approved IXIFI, a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Western Alliance Bancorporation announced that during the first quarter of 2018 Robert Sarver will transition from Chairman and CEO to Executive Chairman. In conjunction with Sarver's change in role, Ken Vecchione will be promoted to Chief Executive Officer, Dale Gibbons to Vice Chairman and Chief Financial Officer, and James Haught to President and Chief Operating Officer, all effective April 1, 2018.

Aqua America announced that President and CEO Christopher H. Franklin has been elected chairman of the board, effective Jan. 1, 2018. Franklin became CEO in July 2015 and has served on the board of directors since October 2015. He succeeds Nicholas DeBenedictis, former CEO, who will continue to serve on the board as chairman emeritus.